In detail.. The Health Organization warns of a “contaminated drug” in Lebanon and Yemen

World Health Organization In a statement, the contaminated lot belonged to a drug "methotrexate;" 50 mg (METHOTREX 50mg) in the WHO Region for the Eastern Mediterranean.

She explained it "The contaminated batch was found in Lebanon AndTo whomafter adverse effects were seen in sick children receiving the drug".

She indicated that the health authorities in the two countries conducted microbiological tests on the remaining sealed vials, the results of which revealed the presence of Pseudomonas aeruginosa, which indicates contamination of the products.

the details

• falls Medication "methotrexate;" It is included in the WHO Model List of Essential Medicines.
• It is an immunosuppressive chemotherapy agent, indicated for the treatment of: cancer AndAutoimmune diseases.
• Pseudomonas aeruginosa infection, which infects the bloodstream, is a serious infection that can lead to death.
• Any contaminated product injected directly into the body can pose severe risks to patients.

contaminated batch

• The manufacturing company of the World Health Organization confirmed that the information regarding the batch number, date of manufacture and expiry date referred to in the alert was in accordance with its internal records.
• The company also confirmed it "It has not yet obtained samples of the suspected products to conduct its confirmatory tests".
• This batch was supposed to be sold exclusively in the Indian markets, and the quantity in Lebanon and Yemen was imported from outside the organized supply chain, so the manufacturing company "It cannot guarantee product safety".

WHO recommendations

• The need to detect contaminated products and withdraw them from circulation, to prevent harm to patients.
• Increase surveillance and vigilance at the level of supply chains in countries and territories potentially affected by this product.
• Increase monitoring at the market level "irregular".
• The need for the competent authorities to notify them (the Health Organization) immediately, if this product is discovered in the markets of their countries.
• The importance of manufacturing companies conducting tests to detect any microbial contamination, before issuing batches of finished products for use.
• The need to obtain medicines through approved and licensed suppliers, and to carefully check the authenticity and physical condition of the products.

“>

explained World Health Organization In a statement, the contaminated batch belonged to the drug “Methotrex 50mg” in the WHO’s Eastern Mediterranean Region.

She explained, “The contaminated batch was found in Lebanon AndTo whomAfter adverse effects have been shown in sick children receiving the drug.

She indicated that the health authorities in the two countries conducted microbiological tests on the remaining sealed vials, the results of which revealed the presence of Pseudomonas aeruginosa, which indicates contamination of the products.

the details

• falls drug “methotrexate” It is included in the WHO Model List of Essential Medicines.
• It is an immunosuppressive chemotherapy agent, indicated for the treatment of: cancer AndAutoimmune diseases.
• Pseudomonas aeruginosa infection, which infects the bloodstream, is a serious infection that can lead to death.
• Any contaminated product injected directly into the body can pose severe risks to patients.

contaminated batch

• The manufacturing company of the World Health Organization confirmed that the information regarding the batch number, date of manufacture and expiry date referred to in the alert was in accordance with its internal records.
• The company also confirmed that it “has not yet obtained samples of the suspected products to conduct its confirmatory tests.”
• This batch was supposed to be sold exclusively in the Indian market, and the quantity in Lebanon and Yemen was imported from outside the regulated supply chain, so the manufacturing company “could not guarantee the safety of the product”.

WHO recommendations

• The need to detect contaminated products and withdraw them from circulation, to prevent harm to patients.
• Increase surveillance and vigilance at the level of supply chains in countries and territories potentially affected by this product.
• Increasing surveillance at the level of “informal” markets.
• The need for the competent authorities to notify them (the Health Organization) immediately, if this product is discovered in the markets of their countries.
• The importance of manufacturing companies conducting tests to detect any microbial contamination, before issuing batches of finished products for use.
• The need to obtain medicines through approved and licensed suppliers, and to carefully check the authenticity and physical condition of the products.